Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya31429EditorialBiological markers of respiratory diseasesChuchalinA Gpulmo_fmba@mail.ru1503201486341310042020Copyright © 2014, Consilium Medicum2014biological markersrespiratory diseasesevidence-based medicineбиологические маркерыреспираторные заболеваниямедицинаоснованная на доказательствах (доказательная медицина)[Cochrane methodology registry. In: The Cochrane Library. Oxford 2001.][Sacket D.L., Straus S.E. Finding and applying evidence during clinical rounds. JAMA 1998; 280: 1336-1338.][Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология (основы доказательной медицины). М: Медиа Сфера 1998; 352.][De Gruttola V.G., Clax P., DeMets D.L. et al. Consideration in the evaluation of surrogate endpоints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22 (5): 485-502.][Woodruff P.G., Modrek B., Choy D.F. et al. T-helper type 2-driven inflammation defines major sub phenotypes of asthma. Am J Respir Crit Care Med 2009; 180 (5): 388-395.][Micheel C.M., Ball J.R., eds. Committee on Qualification of Biomarkes and Surrogate Endpoints in Chronic Disease; Institute of Medicine. Evaluation of Biomarkes and Surrogate Endpoints in Chronic Disease. 2010.][Waterer G. Modern Diagnosis of Community Acquired and Viral Pneumonia: Beyond Conventional Microbiology Culture. Proceedings American Thoracic Society, Postgraduate course #3,4/12.][Porcel J.M., Ruiz-González A., Falguera M. et al. Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. Chest 2007; 131 (5): 1442-1447.][Murdoch D.R., Laing R.T., Cook J.M. The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin Infect Dis 2003; 37 (1): 153-154.][Rello J., Ausina V., Ricart M. et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. 1993. Chest 2009; 104 (4): 1230-1235.][Perlino C. Alcoholism, leukopenia, and pneumococcal sepsis. Am Rev Respir Dis 1984; 132: 757-760.][Carlos W.G., Hage Ch.A. Advances in the non-culture based laboratory diagnosis of cryptococcus and endemic molds. Curr Fungal Infect Rep 2012; 6 (3): 215-220.][Cattamanchi A. Moving beyond smear and culture: rapid diagnosis of tuberculosis and identification of drug resistance. Proceedings American Thoracic Society, 2013. Posgratuate course #3, 1-18.][Light R.W., Lee G., Lee Y.C.G. Textbook of Pleural Disease. Hodder Arnold 2008; 650.][Light R.W., Lee Y.C. Pneumothorax, Chylothorax, Hemothorax, Fibrothorax. In Murray and Nadel's Textbook of respiratory disease. 5th ed. 2010; 2400.][Боткин С.П. Клинические лекции. Под ред. А.Л. Мясникова. 1952.][Sethi S., Wrona C., Eschberger K. et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. AJRCCM 2008; 177 (5): 491-495.][Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Critical care 2010; 14 (1): 15.][Calfee C. Novel biomarkers in ARDS. Proceedings American Thoracic Society 2013. Postgratuate course #3.][Agrawal S. et al. COPD Pulmonary disease, chronic obstructive, severe early-onset. AJRCCM 2013 (in press).]